3D Printed Heart Attack Sensor Costs Just 17 Cents — University of Brighton Breakthrough

A 17-Cent Heart Attack Test

Researchers at the University of Brighton and University of Strathclyde have developed an electrochemical sensor platform that can detect heart attack protein biomarkers in human blood serum — and it costs just 17 cents per test. The breakthrough could dramatically improve early heart attack detection in resource-limited settings.

How It Works

The sensor uses a 3D printed electrode platform combined with electrochemical detection technology. When exposed to blood serum, the sensor can identify specific protein biomarkers that indicate cardiac distress — proteins like troponin that are released into the bloodstream when heart muscle is damaged.

The key innovation is the low-cost electrode construction using 3D printing techniques, which allows for mass production of consistent, reliable sensors at a fraction of traditional manufacturing costs.

Why 17 Cents Matters

Cardiovascular disease remains the leading cause of death globally, and early detection is critical for survival. However, existing diagnostic tools like the troponin immunoassay require expensive laboratory equipment and trained technicians — resources that simply don't exist in many parts of the world.

At 17 cents per test, this sensor platform becomes accessible to:

• Rural clinics in developing nations
• Point-of-care testing in ambulances
• Home health monitoring
• Mass screening programs
• Resource-limited hospitals

The 3D Printing Advantage

3D printing enables the sensor electrodes to be manufactured with precise geometries that maximize the surface area available for electrochemical reactions. This directly translates to higher sensitivity — more surface area means the sensor can detect lower concentrations of biomarkers.

Researchers note that the 3D printing process also allows for rapid iteration and customization, potentially enabling sensors tailored to different biomarker profiles or patient populations.

What's Next

The research team is now working on clinical validation studies and exploring partnerships to bring the technology to market. While additional testing and regulatory approval will be needed, the 17-cent price point represents a potential paradigm shift in cardiac diagnostics accessibility.